A double-blind, vehicle-controlled clinical study to evaluate the efficacy of MAS065D (Xclair™), a hyaluronic acid-based formulation, in the management of radiation-induced dermatitis

G. Primavera, M. Carrera, E. Berardesca, P. Pinnaró, M. Messina, G. Arcangeli

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

This study was designed to assess the efficacy and tolerability of MAS065D (Xclair™) compared to a vehicle control in the management of radiation dermatitis in patients receiving radiotherapy for breast cancer. Twenty patients were randomized blindly to use the two study substances, three times daily, on separate sections of irradiated skin throughout the duration of radiotherapy and for two weeks afterwards. Patients were monitored before therapy, weekly during therapy, and for 2 weeks after radiotherapy was completed. Skin appearance according to National Cancer Institute (NCI) toxicity criteria, erythema rating, transepidermal water loss (TEWL), skin hydration, patients' view of itch, pain, acceptance, and view of each cream and adverse events, were monitored; at the final visit patients and investigators expressed their preference for one of the creams. MAS065D showed statistically significant superiority in the outcomes of NCI grading for radiation dermatitis and erythema. Patients' and investigators' preferences for one of the study substances were statistically in favor of MAS065D. Very few patients recorded nonzero itch and pain scales, so no significant differences emerged between the two groups. It was concluded that MAS065D can provide an effective option for managing radiation dermatitis although further studies are needed to assess its effect on pain and itch.

Original languageEnglish
Pages (from-to)165-171
Number of pages7
JournalCutaneous and Ocular Toxicology
Volume25
Issue number3
DOIs
Publication statusPublished - Sep 1 2006

Fingerprint

Radiodermatitis
Dermatitis
Hyaluronic Acid
Radiotherapy
Radiation
Skin
National Cancer Institute (U.S.)
Erythema
Pain
Research Personnel
Hydration
Toxicity
Patient Preference
enoxolone, hyaluronic acid, levomenol, telmesteine, vitis vinifera drug combination
Clinical Studies
Water
Breast Neoplasms
Therapeutics

Keywords

  • Breast cancer
  • Dermatitis
  • MAS065D
  • Radiotherapy
  • Xclair™

ASJC Scopus subject areas

  • Health, Toxicology and Mutagenesis
  • Ophthalmology
  • Toxicology

Cite this

A double-blind, vehicle-controlled clinical study to evaluate the efficacy of MAS065D (Xclair™), a hyaluronic acid-based formulation, in the management of radiation-induced dermatitis. / Primavera, G.; Carrera, M.; Berardesca, E.; Pinnaró, P.; Messina, M.; Arcangeli, G.

In: Cutaneous and Ocular Toxicology, Vol. 25, No. 3, 01.09.2006, p. 165-171.

Research output: Contribution to journalArticle

@article{397c1534b9634c3096a0ad738181f0f9,
title = "A double-blind, vehicle-controlled clinical study to evaluate the efficacy of MAS065D (Xclair™), a hyaluronic acid-based formulation, in the management of radiation-induced dermatitis",
abstract = "This study was designed to assess the efficacy and tolerability of MAS065D (Xclair™) compared to a vehicle control in the management of radiation dermatitis in patients receiving radiotherapy for breast cancer. Twenty patients were randomized blindly to use the two study substances, three times daily, on separate sections of irradiated skin throughout the duration of radiotherapy and for two weeks afterwards. Patients were monitored before therapy, weekly during therapy, and for 2 weeks after radiotherapy was completed. Skin appearance according to National Cancer Institute (NCI) toxicity criteria, erythema rating, transepidermal water loss (TEWL), skin hydration, patients' view of itch, pain, acceptance, and view of each cream and adverse events, were monitored; at the final visit patients and investigators expressed their preference for one of the creams. MAS065D showed statistically significant superiority in the outcomes of NCI grading for radiation dermatitis and erythema. Patients' and investigators' preferences for one of the study substances were statistically in favor of MAS065D. Very few patients recorded nonzero itch and pain scales, so no significant differences emerged between the two groups. It was concluded that MAS065D can provide an effective option for managing radiation dermatitis although further studies are needed to assess its effect on pain and itch.",
keywords = "Breast cancer, Dermatitis, MAS065D, Radiotherapy, Xclair™",
author = "G. Primavera and M. Carrera and E. Berardesca and P. Pinnar{\'o} and M. Messina and G. Arcangeli",
year = "2006",
month = "9",
day = "1",
doi = "10.1080/15569520600860009",
language = "English",
volume = "25",
pages = "165--171",
journal = "Cutaneous and Ocular Toxicology",
issn = "1556-9527",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - A double-blind, vehicle-controlled clinical study to evaluate the efficacy of MAS065D (Xclair™), a hyaluronic acid-based formulation, in the management of radiation-induced dermatitis

AU - Primavera, G.

AU - Carrera, M.

AU - Berardesca, E.

AU - Pinnaró, P.

AU - Messina, M.

AU - Arcangeli, G.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - This study was designed to assess the efficacy and tolerability of MAS065D (Xclair™) compared to a vehicle control in the management of radiation dermatitis in patients receiving radiotherapy for breast cancer. Twenty patients were randomized blindly to use the two study substances, three times daily, on separate sections of irradiated skin throughout the duration of radiotherapy and for two weeks afterwards. Patients were monitored before therapy, weekly during therapy, and for 2 weeks after radiotherapy was completed. Skin appearance according to National Cancer Institute (NCI) toxicity criteria, erythema rating, transepidermal water loss (TEWL), skin hydration, patients' view of itch, pain, acceptance, and view of each cream and adverse events, were monitored; at the final visit patients and investigators expressed their preference for one of the creams. MAS065D showed statistically significant superiority in the outcomes of NCI grading for radiation dermatitis and erythema. Patients' and investigators' preferences for one of the study substances were statistically in favor of MAS065D. Very few patients recorded nonzero itch and pain scales, so no significant differences emerged between the two groups. It was concluded that MAS065D can provide an effective option for managing radiation dermatitis although further studies are needed to assess its effect on pain and itch.

AB - This study was designed to assess the efficacy and tolerability of MAS065D (Xclair™) compared to a vehicle control in the management of radiation dermatitis in patients receiving radiotherapy for breast cancer. Twenty patients were randomized blindly to use the two study substances, three times daily, on separate sections of irradiated skin throughout the duration of radiotherapy and for two weeks afterwards. Patients were monitored before therapy, weekly during therapy, and for 2 weeks after radiotherapy was completed. Skin appearance according to National Cancer Institute (NCI) toxicity criteria, erythema rating, transepidermal water loss (TEWL), skin hydration, patients' view of itch, pain, acceptance, and view of each cream and adverse events, were monitored; at the final visit patients and investigators expressed their preference for one of the creams. MAS065D showed statistically significant superiority in the outcomes of NCI grading for radiation dermatitis and erythema. Patients' and investigators' preferences for one of the study substances were statistically in favor of MAS065D. Very few patients recorded nonzero itch and pain scales, so no significant differences emerged between the two groups. It was concluded that MAS065D can provide an effective option for managing radiation dermatitis although further studies are needed to assess its effect on pain and itch.

KW - Breast cancer

KW - Dermatitis

KW - MAS065D

KW - Radiotherapy

KW - Xclair™

UR - http://www.scopus.com/inward/record.url?scp=33748765521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748765521&partnerID=8YFLogxK

U2 - 10.1080/15569520600860009

DO - 10.1080/15569520600860009

M3 - Article

C2 - 16980242

AN - SCOPUS:33748765521

VL - 25

SP - 165

EP - 171

JO - Cutaneous and Ocular Toxicology

JF - Cutaneous and Ocular Toxicology

SN - 1556-9527

IS - 3

ER -